Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Adaptimmune Therapeutics PLC
Revenue
Adaptimmune Therapeutics PLC
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
Revenue
$60.3m
|
CAGR 3-Years
148%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Revenue
$6.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Revenue
$1.7m
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Revenue
$27m
|
CAGR 3-Years
37%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Revenue
£249.4m
|
CAGR 3-Years
102%
|
CAGR 5-Years
60%
|
CAGR 10-Years
N/A
|
|
Genus PLC
LSE:GNS
|
Revenue
£673.1m
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
6%
|
Adaptimmune Therapeutics PLC
Revenue Breakdown
Breakdown by Geography
Adaptimmune Therapeutics PLC
Breakdown by Segments
Adaptimmune Therapeutics PLC
Total Revenue:
60.3m
USD
|
Refers To Development Revenue:
60.3m
USD
|
See Also
What is Adaptimmune Therapeutics PLC's Revenue?
Revenue
60.3m
USD
Based on the financial report for Dec 31, 2023, Adaptimmune Therapeutics PLC's Revenue amounts to 60.3m USD.
What is Adaptimmune Therapeutics PLC's Revenue growth rate?
Revenue CAGR 5Y
0%
Over the last year, the Revenue growth was 122%. The average annual Revenue growth rates for Adaptimmune Therapeutics PLC have been 148% over the past three years .